MediLink Therapeutics has partnered with Amgen to explore the therapeutic potential of their B7-H3-targeting ADC YL201 in combination with Amgen’s DLL3- and CD3-targeting BiTE IMDELLTRA in a Phase Ib study for extensive-stage small cell lung cancer (ES-SCLC)

Amgen will lead the global, open-label, multi-center Phase Ib clinical study, which will assess the safety, tolerability, pharmacokinetics, and efficacy of the combination regimen in patients with ES-SCLC

MediLink’s YL201 has shown promising efficacy in a Phase I/II clinical trial for advanced solid tumors, including SCLC, and the results were presented at the ESMO Congress 2024